INTRODUCTION
Mutations in the ataxia-telangiectasia mutated (ATM) gene give rise to the human autosomal recessive disorder ataxiatelangiectasia (A-T) (1, 2) . This is a multisystem disorder characterized by immunodeficiency, cancer predisposition, radiosensitivity, chromosomal instability and neurodegeneration (3). The neuropathological feature of A-T is a diffuse cerebellar degeneration characterized primarily by loss of Purkinje cells and granular neurons, but other regions of the nervous system are also affected, including brain stem nuclei, spinal cord and dorsal root ganglia (4) . This is a rare disorder (1 in 300 000) with global distribution, but has proven to be a paradigm for other autosomal recessive ataxias with overlapping clinical phenotype (5 -8) . This subset of ataxias is linked by defects in genes that code for proteins that protect the genome against DNA damage and neurodegeneration (3) . ATM, the protein mutated in A-T, is a protein kinase that is activated by alterations in chromatin structure (9) , DNA double strand breaks (DSB) (10) and oxidative stress (11) . This protein is recruited to sites of DNA DSB by the Mre11/Rad50/Nbs1 protein complex, where it becomes activated (3) . Once activated, it phosphorylates members of this complex that act as adapters for the control of downstream signaling through other substrates to the cell cycle checkpoints and the DNA repair machinery (12) (13) (14) . It is estimated that ATM may phosphorylate as many as 700 substrates to control a variety of cellular processes (15, 16) . At present it is not clear which of these substrates might be important in protecting against neurodegeneration.
To date, the majority of studies on A-T have used fibroblast and lymphoblastoid cells as well as animal models (17, 18) . Mouse models of A-T fail to show neurodegeneration. To investigate the role of ATM in neurodegeneration, it is desirable to have model systems more representative of human neurons. For example, knockdown or inhibition of ATM in human embryonic stem (ES) cells and in an immortalized human neural stem-cell line has allowed investigation into its role in stem cells (19, 20) . Another approach is to generate patient-derived stem cells and differentiate them into neurons as we demonstrated recently using induced pluripotent stem cells (iPSC) derived from fibroblasts from an A-T patient (21) . In the present study, we generated tissue stem cells from the olfactory mucosa of patients with A-T. This approach provides patient-derived neural stem cells without the genetic manipulation required for ES cell and iPSC investigations. The olfactory mucosa, the organ of smell in the nose, is an accessible regenerating neural tissue containing stem cells that replenish the sensory neurons (22, 23) . Human olfactory stem cells are multipotent, able to differentiate into neurons, astrocytes and oligodendrocytes and non-neural cell types (24) . These stem cells are initially propagated as neurospheres and then grown as adherent 'olfactory neurosphere-derived' (ONS) cells with characteristics of both neural and mesenchymal stem cells (25, 26) . As novel models of brain disease, ONS cells from patients are compared with those from healthy controls to identify disease-specific alterations in gene and protein expression and cell functions in genetically complex nervous system diseases [schizophrenia and Parkinson's disease (26 -29) and monogenic disease, familial dysautonomia (30) ]. Derived from neural tissue, ONS cells provide cellular models that are potentially more informative of brain diseases than patient-derived fibroblasts and lymphoblasts (31) .
The aim of this study was to discover if it is possible to generate ONS cells from patients with the genetic disorder A-T and, if so, to compare these with ONS cells from healthy controls to reveal the cellular phenotype of ATM mutation in these cells. Our hypothesis is that patient-derived ONS cells will be compromised in functions related to mutations of ATM that can be ameliorated by genetic correction of the mutation. These cells showed an A-T cellular phenotype and the capacity to form neurons. Transfection with full-length ATM cDNA corrected the A-T cellular phenotype. This represents an excellent patient-derived model system to generate neuronal cell types, pertinent to A-T, as a means of understanding the cellular pathology of this disorder with potential as a cellular platform for screening for small molecular therapeutics for this disorder.
RESULTS

Growth, morphology and immunophenotype of ONS cells from A-T patients and controls
The clinical features and other characteristics of these patients are outlined in Table 1 . A-T patient-derived neurospheres and ONS cells were similar to those from family members and healthy controls, with no obvious differences in morphology ( Fig. 1A and B) . Growth rates were similar for the different cell types, and karyotypic analysis did not reveal any chromosomal abnormalities in the A-T ONS cells (results not shown). Flow cytometric analysis was carried out to assess the similarity of cell types within the cultures using a set of markers for neural stem cells and progenitors and for mesenchymal stem cells (26) . This analysis confirmed that ONS cells derived from A-T patients (homozygotes), their parents (heterozygotes) and healthy controls (control) had very similar immunophenotypes ( Fig. 1C ; Table 2 ). Two-way analysis of variance (ANOVA) indicated a significant difference among the immunomarkers in Table 2 (F 7,13 ¼ 400.2, P , 0.001), but no difference among the patient and control groups (F 3,5 ¼ 1.6, P ¼ 0.31), indicating that the cell populations were composed of similar cell types.
A-T ONS cells show the expected 'A-T cellular phenotype'
Mutation analysis in fibroblasts derived from A-T patients revealed that ATNP32ABR was homozygous for the frameshift change IVS58-1G . A that was predicted to delete exon 58, whereas patient ATNP30ABR had two single nucleotide deletions (8368delA and 7570delG), predicted to result in prematurely terminated ATM protein (Table 1) . Mutations were not determined for ATNP35ABR. No ATM protein was detected in ONS cells from ATNP30ABR, and only low levels were detected for ATNP32ABR and ATNP35ABR ( Fig. 2A) . Phospho-specific antibodies against three separate auto-phosphorylation sites on ATM were used to measure ATM activation (32) . This analysis revealed a radiationinduced increase in the controls, but no ATM kinase activity was evident in any of the A-T patient ONS cells ( Fig. 2A) . A-T cells can be characterized by defective radiation-induced signaling through a number of downstream substrates (3, 9) . The results in Figure 2B demonstrate that all A-T ONS cells failed to show radiation-induced phosphorylation of SMC1, Kap1, NBN, Chk2 and p53, substrates involved in DNA repair and cell cycle control and are dependent on ATM. Radiation-induced phosphorylation of all these substrates was observed in the control ONS cells (CNP09ABR, CNP017ABR). These data are supportive of the A-T clinical diagnosis (Table 1) .
Increased sensitivity to radiation is widely observed in a variety of A-T cell types (3, 33) . Exposure of A-T ONS cells to ionizing radiation revealed that they were significantly more sensitive than controls as determined by clonogenic cell survival (Fig. 2C , P , 0.001). It is of interest that A-T heterozygote ONS cells were intermediate between control and A-T homozygotes in radiation survival that was reported previously for A-T heterozygote fibroblast and lymphoblastoid cells (33) . We also measured repair of DNA DSB using
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Human Molecular Genetics, 2013, Vol. 22, No. 12 appearance and loss of gH2AX and 53BPI foci (34) . Previous data reveal that there is a defect in the repair in a small component of DNA DSB (heterochromatin localized) in A-T cells representing about 10% of breaks (35, 36) . These foci co-localized in both control and A-T ONS cells. Although the same number of foci formed in both cell types at 1 h postirradiation, the A-T patient-derived ONS cells failed to repair these DSB to the same extent; loss of foci at 8 and 24 h postirradiation was less in A-T ONS cells than in control (Supplementary Material, Fig. S1A , P , 0.05). Because there is also evidence that ATM is activated by oxidative damage (11) and because oxidative stress is implicated in neurodegeneration in A-T (3,5,6), we determined whether there was evidence of oxidative damage in A-T ONS. We examined oxidative damage to DNA (8-oxo-dG) and to protein (nitrotyrosination), but found no evidence for elevated levels of either form of damage in A-T ONS (results not shown). This was also the case after induction of damage with H 2 O 2.
A-T cells from other tissues are characterized by defective cell cycle checkpoint activation after radiation exposure (37) . To confirm that A-T ONS cells recapitulate this A-T cellular phenotype, we determined the integrity of the intra-S phase and G2/M phase checkpoints. The G2/M phase checkpoint is assessed by the number of cells entering mitosis 2 h after irradiation, determined by histone H3 phosphorylation (38) . In two control ONS cell lines, irradiation caused a dramatic reduction in histone H3 phosphorylation, in keeping with activation of the G2/M checkpoint (Supplementary Material, Fig. S1B ). In contrast, this checkpoint was defective in A-T ONS cells, where the extent of inhibition was only 50-60%. The intra-S phase checkpoint was assessed using a DNA fiber assay in which the number of new initiations of DNA synthesis is expressed as a percentage of total DNA elongations, for irradiated and unirradiated cells (14, 39) . The results in Supplementary Material, Figure S1C show that in control cells after 2 Gy irradiation, DNA synthesis is reduced to approximately 40% of that in non-irradiated cells. In patient-derived A-T ONS cells exposed to the same radiation dose, DNA synthesis remained at approximately 90% of non-irradiated cells, demonstrating the presence of radioresistant DNA synthesis, a characteristic of other cells derived from A-T patients (40) .
Genetic correction of the A-T cellular phenotype
We sought to rescue the A-T cellular phenotype using fulllength ATM cDNA. A-T ONS cells (ATNP30ABR) were transfected with YFP-ATM (31) . The success of genetic correction was measured functionally by the capacity to form ATM foci (ATMpS1981) at sites of DNA DSB and by the appearance of downstream substrate phosphorylation on SMC1. Whereas A-T cells showed the presence of DNA DSB (gH2AX foci) in response to radiation, no ATM pS1981 foci were evident, but in control cells, ATM pS1981 foci co-localized with gH2AX foci (Fig. 3A) . On the other hand, when A-T ONS cells were transfected with YFP-ATM, exposure to radiation led to the appearance of ATM pS1981 foci, demonstrating ATM expression and activation in these cells (Fig. 3B ). Not surprisingly, radiation-induced phosphorylation of the ATM-dependent SMC1 substrate was completely defective in A-T ONS cells exposed to radiation, but control cells showed a strong response (Fig. 3C ). The introduction of YFP-ATM into A-T ONS cells led to the appearance of radiation-induced SMC1 phosphorylation (Fig. 3D ). These experiments show that correction of the genetic mutation in A-T cells restores ATM functions to these cells.
Gene expression profiling of patient and control cells
Gene expression profiling was undertaken to determine mRNA transcription in A-T patient-derived and control-derived ONS cells. Patient and control cells expressed 14 756 and 14 555 probes, respectively, of which 14 054 probes (96%) were expressed in common, further demonstrating the basic similarity in ONS cells from patients and controls. The reproducibility of cell culture and gene expression profiling was tested by comparing the raw fluorescence values from the microarray between biological replicates (separate aliquots of ONS cells from each patient and control, grown independently). The correlation coefficients between the fluorescence associated with each of the expressed genes for each replicate were very high, with r 2 averaging 0.98 for all replicate comparisons (three patients and three controls). Within-group correlation coefficients were also high (r 2 ¼ 0.96 and 0.94 for patient and control cells, respectively). Finally, between-groups correlation was also very high (r 2 ¼ 0.94), again reflecting the general similarity between patient and control cells and the large overlap in expressed genes. Principal component analysis on the 14 054 detected probes demonstrated that 26% of the variance in gene expression was driven by the between-groups difference (i.e. the A-T phenotype, represented in the second component, PC2: Supplementary Material, Fig. S2 ). There were 665 genes that were differentially expressed in patient and control cells (P , 0.01; Supplementary Material, Table S1 ). These 665 differentially expressed genes were subjected to gene ontology (GO) analysis. This identified 'cell cycle', 'cell death' and 'DNA damage response' as the categories with statistically significant numbers of differentially expressed genes in patient cells when compared with control cells (Table 3) , data extracted from Supplementary Material, Table S1 . Of note is the differential expression of six genes, whose proteins interact with ATM: NFKB1A, CREB1, MDC1 and CHEK2 (overexpressed in patient cells) and PTS and RAD17 (underexpressed in patient cells when compared with controls).
Differentiation of ONS cells into immature neurons
After neuronal induction, A-T and control ONS were stained for bIII-tubulin, MAP2 and doublecortin, markers of neuronal differentiation (41) . Use of the immature neuron marker bIIItubulin stained 60% of ONS cells (Fig. 4A i, iv) and 100% of the immature neurons (Fig. 4B i, iv) for both A-T and controls. A second marker of immature neurons MAP2 labeled 100% of ONS (Fig. 4A ii, v) and neuronal progenitors (Fig. 4B , ii, v) for A-T and control. The neuronal marker doublecortin, that detects cells later in the lineage, failed to stain ONS cells, but stained 30% of the immature neurons in both cases (Fig. 4A, iii, vi; Fig. 4B , iii, vi). Morphological examination revealed that the extent of differentiation was reduced in A-T neuronal progenitors (Fig. 4C ii) when compared with control ( Fig. 4C iv) after 11 days of differentiation. Neuronal differentiation was assessed by quantifying the proportion of cells with four or more neurites ≥10 mm in length (Fig. 4D) (control: 58.5% + 5.0, n ¼ 3 * * ; A-T: 9.0% + 1.4, n ¼ 3 * * ; P , 0.03); total length of neurites per cell (Fig. 4E ) (control: 6165 + 483, n ¼ 3,A-T:3095 + 68; P , 0.007) and average length of neurites in bipolar cells (Fig. 4F ) (control:129 + 23 n ¼ 3,A-T:75 + 13; P , 0.035) In all parameters, the extent of differentiation was significantly greater in control than in A-T cells.
DISCUSSION
We show here: (i) that ONS cells derived from patients with A-T have functional deficits associated with mutations in ATM, (ii) that these deficits can be genetically corrected and (iii) that neurite outgrowth is impaired in patient-derived ONS cells after differentiation into immature neurons. After radiation exposure, these cells lack ATM kinase activity and have reduced survival, impaired ability to repair DNA DSB and defective cell cycle control. Compared with ONS cells derived from healthy controls, patient-derived ONS cells had similar morphology and immunophenotype and similar growth characteristics in vitro. Gene expression profiling indicated similar gene expression in patient-derived and 
Flow cytometric analysis giving the percentage of cells immunopositive for each of the antibodies (left column) on A-T homozygote and control ONS cell lines (n varies between two and four for both groups) and two A-T heterozygote parent controls. Data are expressed as mean + SEM.
control-derived ONS cells except for 665 genes (5% of total) that were differentially expressed. These differentially expressed genes were clustered in the GO classes of 'cell cycle', 'cell death' and 'DNA damage response', in agreement with the functional deficits in patient-derived ONS cells. We show that it is possible to introduce wild-type ATM cDNA Figure 2 . ATM activation and signaling are defective in A-T ONS cells. (A) Cells were exposed to 6 Gy radiation and incubated for 1 h prior to preparation of extracts. ATM activation was determined by immunoprecipitation, followed by immunoblotting with phospho-specific antibodies against three autophosphorylation sites on ATM, pS367, pS1981 and pS2996 as described by Kozlov et al. (54) . ATM protein was detected with an antibody specific for this protein.
Immunoprecipitated ATM samples were run on 5%/12% biphasic SDS-PAGE. The top 5% of the gel was used for immunoblotting and the 12% section was stained with Coomassie Blue and served as a loading control for ATM immunoprecipitations. Two control (CNP09ABR and CNP017ABR) and three A-T (ATNP30ABR, ATNP32ABR and ATNP35ABR) ONS cells were employed. (B) Radiation-induced phosphorylation through a number of ATM-dependent substrates (56) . These substrates include p53, Chk2 protein kinase, NBN a member of the MRN complex, the chromatin binding protein KAP-1 and structural maintenance of chromosome protein 1, SMC1. Cells were exposed to 6 Gy radiation and incubated for 1 h prior to preparation of extracts for immunoblotting with antibodies against individual proteins and ATM-dependent phosphorylated sites on these proteins. Cell lines were the same as in A. b-actin was used as a loading control. into a patient-derived ONS cell line and that this corrected the functional deficits associated with mutations in this gene. Finally, we show that when patient-derived ONSs were differentiated into neurons, they showed deficits in neurite formation when compared with control-derived ONS cells exposed to the same treatment.
Patient-derived ONS cells have impaired response to irradiation
There were no overt differences in the ability to generate patient-derived and control-derived ONS cells. Under standard culture conditions, patient and control cells were essentially indistinguishable, in common with ONS cells derived from patients with other neurological conditions, schizophrenia and Parkinson's disease (26, 29) . The derived populations were of similar morphology and similar cellular composition, as indicated by similar expression of cell surface and other markers, assessed by flow cytometry. Neither patient-derived nor control-derived ONS cells showed any karyotypic abnormalities, indicating that prolonged periods in vitro did not affect chromosomal stability. A-T patient-derived ONS cells showed differential expression of genes associated with functions of ATM, revealing that the lack of ATM kinase activity in these cells results in homeostatic regulation of expression of genes associated with downstream cell functions, including cell cycle, cell death and DNA damage response. These findings are consistent with our previous observations that ONS cells derived from patients with schizophrenia or Parkinson's disease also show underlying disease-associated gene expression without obvious differences in cell morphology and immunophenotype when compared with control-derived cells (26, 29) . Increased sensitivity to radiation is widely observed in a variety of A-T cell types (3, 33) . A-T cells can be characterized by defective radiation-induced signaling through a number of downstream substrates (3, 9) . A-T patient-derived ONS cells have reduced or absent levels of ATM protein and lack of phosphorylation of numerous downstream substrates after irradiation. Control-derived ONS cells did not show these deficits. A-T patient-derived ONS cells showed significant disease-associated differences in cell functions when challenged with radiation, using standard assays (14, 36, 37) . Patient-derived cell survival was significantly reduced after exposure to radiation when compared with ONS cells from healthy controls. There was evidence of an ATM dosage effect, demonstrated by an intermediate survival rate in ONS cells from heterozygous parents, as observed previously with lymphoblastoid cells (33) . Patient-derived cells showed defective radiation-induced signaling and significant impairment of repair of DNA DSB after irradiation, and, when compared with control cells, patient-derived cells were impaired in their S-phase and G2/M checkpoint controls as measured by radioresistant DNA synthesis and mitotic phosphorylation of histone H3. These observations demonstrate a clear diseasespecific cellular phenotype in patient-derived ONS cells when compared with controls. The specificity of the A-T cellular phenotype was tested by correcting the genetic mutation in one patient-derived ONS cell line by introduction of fulllength ATM cDNA (42) . This manipulation corrected the deficit in ATM-dependent phosphorylation of one of its substrates, SMC1, and corrected the impairment of DNA double strand break repair.
Patient-derived ONS cells have impaired neuronal differentiation
Neurodegeneration remains the most debilitating aspect of the A-T phenotype (3, 5) . It is a progressive cerebellar degeneration accompanied by ectopic distribution and loss of Purkinje cells with other cell types such as granular cells also being affected (4) . Changes in other parts of the central nervous system are more diffusely distributed, especially in older patients, including changes in the spinal cord, spinal ganglia and brain stem (4) . No animal model has been generated that recapitulates the neurodegeneration seen in patients (18) .
A-T patient-derived ONS cells showed impaired neuronal differentiation when compared with control-derived ONS cells when exposed to the same culture conditions. Fewer patient cells had neurites, and the average length of neurites was shorter in patient cells when compared with control cells. This is very reminiscent of Purkinje neurons from the Atm-deficient mouse that died more readily in culture and failed to show dendritogenesis to the same extent as Atm +/+ mice (43) . In addition, Atm 2/2 neural progenitors are less able to respond to environmental cues that promote neuronal differentiation, and this abnormality is magnified in vitro (44) . In contrast, when ATM was knocked down using shRNA in neural precursor cells differentiated from HES-1 cell line cells (20) , the ATM-dependent DNA damage response was abolished, but neuronal differentiation was not affected. Similarly, knockdown of ATM in an immortalized human neuronal stem-cell line abrogated the DNA damage response, but failed to impair neurogenesis (19) . Neither of these cell lines was derived from A-T patient cells, suggesting that patient-derived ONS cells can provide greater insight when compared with model systems that experimentally manipulate ATM levels. 
Patient-derived stem cell models of A-T
A recent report describes the generation of iPSCs from A-T patients using lentiviral constructs expressing Oct4, Sox2, Klf4 and c-Myc that were employed to reprogram fibroblasts (21) . In that study, the efficiency of generating iPSC clones from A-T fibroblasts was low, 4% of that in controls. In addition, only a subset of A-T clones displayed characteristics of multipotent cells that maintained long-term self-renewal. Of these, only a few displayed normal karyotype with increasing passage number, although some maintained karyotypic stability for more than 20 passages (21) . The iPSCs made from embryonic fibroblasts of an Atm-deficient mouse had abnormal genome structures with continuing passage, and the efficiency of iPSC generation was low (,20%) (45) . The low efficiency in human and mouse may be intrinsic to A-T cells because the DNA damage response pathways are activated to remove cells with chromosomal damage during reprograming (46) . A-T is one of a number of syndromes characterized by genome instability that could interfere with reprograming. For example, Fanconi anemia also causes genome instability, and in one report, iPSCs could not be generated from patient-derived fibroblasts until the mutation was corrected (47) . In mouse, reprograming efficiency of fibroblasts was 10% with Fanca 2/2 and 3.8% with Fanc 2/2 mouse, and iPSC generation from Fanconi anemia patient-derived fibroblasts required hypoxic conditions (48) . In contrast, ONS cells are efficiently 
MATERIALS AND METHODS
Participants and nasal biopsies
Nasal biopsy samples were collected from controls, A-T homozygotes and their A-T heterozygote parents as an outpatient procedure as described previously (52) . These samples were obtained with informed consent in accordance with the Australian NHMRC Code of Practice for Human Experimentation and approved by the Queensland Children's Health Services (RCH) and Griffith University Human Ethics Committees. A-T patients were diagnosed after attendance at the A-T Clinic, University of Queensland Centre for Clinical Research, Brisbane, Australia. Controls were recruited as part of a separate study described previously (19) . Skin biopsies were also taken from A-T patients with ethical approval to establish fibroblast lines that were used to determine ATM status and mutations. The nomenclature used for ONS A-T cells is ATNPxABR, where AT refers to the A-T patients; NP is nasal progenitor; x is the number given to the patient and ABR is Australia, Brisbane, keeping with previous nomenclature for A-T cells (33) . The same applies for control ONS.
Establishment of ONS-derived cells from patients and control
Following biopsy, tissue was placed in cold Dulbecco's Modified Eagle's Medium/Ham F-12 (DMEM/F12; JRH Biosciences) containing 10% fetal bovine serum (FBS, GibcoBRL) and 1% streptomycin / penicillin (GibcoBRL). Olfactory cell suspensions were generated from digested olfactory lamina propria and olfactory epithelium using dispase II and collagenase H digestion with mechanical trituration (26) . These primary cultures were grown in DMEM/F12 supplemented with 10% FBS for 3 days before passaging into poly-L-lysine pre-treated flasks and culturing in neurosphere media to produce neurospheres and ONS-derived cells. Nomenclature for controls, A-T homozygote and A-T heterozygote ONS cells were in accordance with those previously established for A-T lymphoblastoid cell lines and fibroblasts (33) .
Gene expression analysis
Gene expression profiling was undertaken as described previously (29) . Briefly, total RNA 500 ng was labeled using Illumina w TotalPrep TM RNA Amplification Kit and hybridized to HumanHT-12 v4 BeadChip (Illumina). The raw data were background adjusted and quantile normalized using the Lumi package in R/BioConductor (53) . A list of differentially expressed genes expressed in the ONS cells was produced by two stage filtering. First, a gene (probe) was identified as 'detected' in patient and control cells if (i) the probe had a detection of P-value ,0.01 in (ii) both replicates of all the three individuals in each patient or control group. Genes that were differentially expressed in disease and control samples were identified by subjecting the gene list to a parametric two-way ANOVA (P ≤ 0.05) with disease status and replicate as main effects. The list of differentially expressed genes was then assessed for 'over-representation' in defined pathways and GO functions using Fisher's exact test (P , 0.01) calculated in 'ingenuity pathway analysis' (http://www. ingenuity.com). ONS cell expression patterns were investigated using principal component analysis. Microarray data were deposited into ArrayExpress (http://www.ebi.ac.uk/arra yexpress/Accession Number E-MTAB-1217).
Cell survival
Clonogenic cell survival after exposure to radiation was carried out as described previously (33) . Control, A-T homozygote and A-T heterozygote ONS, cells were irradiated with 1 -4 Gy of gamma rays and plated out to determine survival by counting colonies. Survival was expressed as the percentage of irradiated/unirradiated cells. Error bars represent SEM using data from three separate experiments.
ATM kinase assay
For kinase assays, ONS cells were irradiated as indicated in Results. ATM immunoprecipitations were prepared with ATM-5BA antibody (54) and protein G-Sepharose for 4 h at 48C. ATM protein kinase assays were prepared as described previously (32) .
DNA replication labeling and DNA fiber spreads: S phase checkpoint
A-T and control ONS cells were labeled consecutively with 15 mM Chlorodeoxyuridine (CldU) for 20 min including a mock or 5 Gy treatment and then a further 20 min with 15 mM Iododeoxyuridine (IdU). DNA fibers were prepared as described previously to determine radioresistant DNA synthesis (14, 39) . Briefly, 2 ml of cells (1 × 10 6 cells/ml) were mixed with 6 ml lysis solution (0.5% SDS, 200 mM TrisHCl pH 7.4 and 50 mM EDTA), and after 10 min, slides were tilted to 158 to spread the DNA fibers. Slides were air dried both pre-and post-fixation in methanol/acetic acid (3:1). DNA fibers were denatured in 2.5 M HCl for 60 min and immunolabeled with rat monoclonal anti-bromodeoxyuridine (BrdU) (BU1/75, Abcam) and anti-rat Alexa-Fluor488 conjugated secondary antibody (Molecular Probes) to label CldU. IdU was subsequently labeled with mouse monoclonal antiBrdU (BD) and donkey anti-mouse Alexa-Fluor594 conjugated secondary antibody (Molecular Probes). DNA tracks were scored (300 -500) for each cell line for mock and 5 Gy treatments. The percentage of new DNA tracks was determined (new initiations/total elongations × 100) and the standard deviation was calculated form three independent experiments.
G2/M checkpoint: mitotic phosphorylation of histone H3-pS10
This assay was carried out as described previously (38) . In short: control and A-T ONS cells were plated on coverslips in six well plates at a density of 5000 cells/cm 2 24 h after irradiation at 2 Gy. Coverslips were processed as described under immunofluorescence methods and stained with anti-phospho-histone H3 (Ser10) at 1:100 dilution to visualize mitotic cells after irradiation. Images were acquired at 10× and analyzed using Velocity 6.1.1 (PerkinElmer).
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Correcting aspects of the A-T cellular phenotype in A-T ONS cells ATNP32ABR ONS cells were transfected with a full-length ATM cDNA-YFP tagged plasmid (42) . The cells were transfected using the Neon transfection system (Invitrogen), plated out on cover slips and allowed to recover in media for 24 h. Cells on cover slips were irradiated at 2 Gy and incubated for 1 h prior to washing and fixing as described under immunofluorescence microscopy. Cells were incubated with ATM pS1981 antibody (1:100) to detect ATM activation. DNA DSB were detected with gH2AX. ATM signaling was detected using an antibody against SMC1 pS957. Images were captured using a Zeiss Axioskop compound microscope equipped with an Axiocam MRmcamera and AxioVision software.
Differentiation of ONS into immature neurons
ONS cells were differentiated along the neuronal lineage using a method previously described (26) . Briefly, control and A-T ONS cells were grown in Neurobasal culture medium supplemented with B27 GlutaMAX and 20 mM glutamic acid for 11 and 22 days with media changed every 3 days. Cells were imaged daily for changes in morphology using an Olympus CKX41 microscope equipped with a MicroPublisher 3.3 RTv Camera (Q Imaging). The length of neurites in neuronlike cells was measured using the Image J software.
Flow cytometry
ONS cells were first fixed in paraformaldehyde (4% in HBSS) for 10 min at room temperature (RT Table S2 ). Percentage positivity was determined by the SED (super-enhanced Dmax) subtraction method (55) .
Lysate preparations, immunoprecipitations and western blotting
ONS cell extracts were prepared by lysis in universal buffer, and for immunoprecipitations, lysates were pre-cleared with protein A beads and then incubated with the specific antibody for 4 h at 48C prior to separation on SDS-PAGE and transferred to nitrocellulose for immunoblotting as described previously. KAP-1 and KAP-1pS824 (rabbit polyclonal) were purchased from Novus Biologicals, USA; anti-FLAG and anti-b Actin from Sigma; anti-rabbit p53 and anti-mouse p53 Ser15 from Cell Signalling Technology, MA, USA; antimouse monoclonal antibodies to SMCI Ser957 and NBS, Ser343 from Upstate, USA; anti-rabbit Chk2 and Chk2 pT68 from Abcam, UK, anti-rabbit ATM Ser 1981 from Rockland, USA; and anti-ATM and Mre11 (mouse monoclonals) were from GeneTex, USA. Anti-mouse and anti-rabbit secondary antibodies were purchased form Millipore, USA and Rockland, USA, respectively. Immunoblottings and immunoprecipitations were carried out according to the manufacturer's directions. Membranes were visualized using enhanced chemiluminescence (Perkin Elmer Life Science).
Immunofluorescence microscopy
Control and A-T ONS cells were seeded onto coverslips in 12-well plates for 24 h prior to treatment with irradiation (5 Gy) and allowed to recover for 1 h. Cells were fixed in 2% paraformaldehyde at RT for 10 min, permeabilized in 0.5% Triton X-100 for 30 min and then blocked in PBS containing 5% BSA fraction V for 1 h at RT. Primary antibody incubations of either 53BP1 (Cell Signalling; 1:300) or gH2AX (Upstate; 1:300) were performed in BSA blocking solution for 1 h at RT. After washing with PBS, cells were incubated with anti-rabbit Alexa-Fluor594 (Invitrogen) and anti-mouse Alexa-Fluor488 (Invitrogen) at 1:1000 dilution for 1 h at RT. Nuclei were counterstained with 4 ′ ,6-diamidino-2-phenylindole (DAPI) for 10 min at RT. After three final washing steps, the coverslips were mounted in Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA). Images were captured using a Zeiss Axioskop compound microscope equipped with an Axiocam MRM camera and Axiovision software.
Labeling of cells for neuronal markers
Both ONS cells and immature neurons were fixed in 100% methanol for 5 min, washed once in PBS and then blocked in PBS containing 5% BSA fraction V for 30 min at RT. Primary antibody incubations of either Beta III tubulin (Covance 1:400), doublecortin (Cell Signalling, 1:200) or MAP2 (Sigma-Aldrich 1:100) were performed in BSA blocking solution for 1 h at RT, followed by incubation with anti-rabbit Alexa-Fluor488 (Invitrogen) or anti-mouse Alexa-Fluor488 (Invitrogen). Nuclei were counterstained with DAPI, and images captured using an Olympus 1X 70 microscope equipped with spot imaging solutions software and an Olympus U-TV1X-2 camera.
Statistical analysis
Data are expressed as mean + SEM. Gene expression data were analyzed as described above. Gene expression comparisons were corrected for multiple testing (Benjamini and Hochberg correction) with statistical significance ascribed at a ¼ 0.01. Statistical significance for GO analysis was ascribed at a ¼ 0.001. ANOVA was performed using SPSS v20. Pairwise comparisons of cell function data were made with two-tailed t-tests with statistical significance ascribed at a ¼ 0.05.
